Patents by Inventor Laurie H. Glimcher

Laurie H. Glimcher has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 10655130
    Abstract: Described herein is a previously unknown function of XBP1 in triple-negative breast cancer (TNBC). It is shown that XBP1 is preferentially spliced and activated in TNBC, and that deletion of XBP1 significantly blocks triple negative breast tumor growth. Strikingly, XBP1 is required for the self-renewal of breast tumor initiating cells (TICs). Genome-wide mapping of the XBP1 transcriptional regulatory network identified a fundamental role for XBP1 in regulating the response to hypoxia via the transcription factor hypoxia-inducible factor 1? (HIF1?). Importantly, activation of this pathway appears to carry prognostic implications, as expression of the XBP1-dependent signature is associated with shorter survival times in human TNBC.
    Type: Grant
    Filed: February 23, 2017
    Date of Patent: May 19, 2020
    Assignee: Cornell University
    Inventors: Laurie H. Glimcher, Xi Chen
  • Patent number: 10450566
    Abstract: Described herein is a previously unknown function of XBP1 in controlling anti-tumor immunity. It is shown that inhibiting XBP1 in tumor-associated dendritic cells inhibits tumor growth and induces protective anti-tumor immune responses.
    Type: Grant
    Filed: March 14, 2018
    Date of Patent: October 22, 2019
    Assignee: Cornell University
    Inventors: Juan R. Cubillos-Ruiz, Laurie H. Glimcher
  • Patent number: 10421965
    Abstract: Described herein is a previously unknown function of XBP1 in controlling anti-tumor immunity. It is shown that inhibiting XBP1 in tumor-associated dendritic cells inhibits tumor growth and induces protective anti-tumor immune responses.
    Type: Grant
    Filed: January 23, 2018
    Date of Patent: September 24, 2019
    Assignee: Cornell University
    Inventors: Juan R. Cubillos-Ruiz, Laurie H. Glimcher
  • Publication number: 20190016706
    Abstract: Described herein are IRE1? inhibitors, compositions containing such inhibitors, and methods of treatment that include administration of such compounds. Exemplary compounds are provided throughout the application.
    Type: Application
    Filed: August 29, 2018
    Publication date: January 17, 2019
    Inventors: Laurie H. Glimcher, Sarah Elizabeth Bettigole, Juan Rodrigo Cubillos-Ruiz, Joseph P. Vacca
  • Patent number: 10125123
    Abstract: Described herein are IRE1? inhibitors, compositions containing such inhibitors, and methods of treatment that include administration of such compounds. Exemplary compounds are provided throughout the application.
    Type: Grant
    Filed: March 3, 2017
    Date of Patent: November 13, 2018
    Assignee: CORNELL UNIVERSITY
    Inventors: Laurie H. Glimcher, Sarah Elizabeth Bettigole, Juan Rodrigo Cubillos Ruiz, Joseph P. Vacca
  • Publication number: 20180258426
    Abstract: Described herein is a previously unknown function of XBP1 in controlling anti-tumor immunity. It is shown that inhibiting XBP1 in tumor-associated dendritic cells inhibits tumor growth and induces protective anti-tumor immune responses.
    Type: Application
    Filed: January 23, 2018
    Publication date: September 13, 2018
    Inventors: Juan R. Cubillos-Ruiz, Laurie H. Glimcher
  • Publication number: 20180201933
    Abstract: Described herein is a previously unknown function of XBP1 in controlling anti-tumor immunity. It is shown that inhibiting XBP1 in tumor-associated dendritic cells inhibits tumor growth and induces protective anti-tumor immune responses.
    Type: Application
    Filed: March 14, 2018
    Publication date: July 19, 2018
    Inventors: Juan R. Cubillios-Ruiz, Laurie H. Glimcher
  • Patent number: 9956236
    Abstract: The invention provides, e.g., compositions and methods for increasing activation of immune cells.
    Type: Grant
    Filed: February 7, 2012
    Date of Patent: May 1, 2018
    Assignee: Cornell University
    Inventors: Laurie H. Glimcher, Sarah Bettigole, Fabio Martinon
  • Patent number: 9957506
    Abstract: Described herein is a previously unknown function of XBP1 in controlling anti-tumor immunity. It is shown that inhibiting XBP1 in tumor-associated dendritic cells inhibits tumor growth and induces protective anti-tumor immune responses.
    Type: Grant
    Filed: September 25, 2014
    Date of Patent: May 1, 2018
    Assignee: Cornell University
    Inventors: Juan R. Cubillos-Ruiz, Laurie H. Glimcher
  • Publication number: 20170252350
    Abstract: Described herein are IRE1? in inhibitors, compositions containing such inhibitors, and methods of treatment that include administration of such compounds. Exemplary compounds are provided throughout the application.
    Type: Application
    Filed: March 3, 2017
    Publication date: September 7, 2017
    Inventors: Laurie H. Glimcher, Sarah Elizabeth Bettigole, Juan Rodrigo Cubillos Ruiz
  • Publication number: 20170253590
    Abstract: Described herein are IRE1? inhibitors, compositions containing such inhibitors, and methods of treatment that include administration of such compounds. Exemplary compounds are provided throughout the application.
    Type: Application
    Filed: March 3, 2017
    Publication date: September 7, 2017
    Inventors: Laurie H. Glimcher, Sarah Elizabeth Bettigole, Juan Rodrigo Cubillos Ruiz, Joseph P. Vacca
  • Patent number: 9745589
    Abstract: This invention is based, at least in part, on the discovery that Shn2 and Shn3 play an important role in skeletal remodeling and skeletal patterning. Accordingly, the present invention provides methods for identifying medulators of Shn2 activity and methods for modulating bone formation and mineralization and Shn2-associated disorders using agents that modulate Shn2 expression and/or activity, in addition to methods for modulating Shn2 and Shn3.
    Type: Grant
    Filed: January 13, 2011
    Date of Patent: August 29, 2017
    Assignee: Cornell University
    Inventors: Laurie H. Glimcher, Dallas C. Jones, Marc Wein
  • Publication number: 20170240903
    Abstract: Described herein is a previously unknown function of XBP1 in triple-negative breast cancer (TNBC). It is shown that XBP1 is preferentially spliced and activated in TNBC, and that deletion of XBP1 significantly blocks triple negative breast tumor growth. Strikingly, XBP1 is required for the self-renewal of breast tumor initiating cells (TICs). Genome-wide mapping of the XBP1 transcriptional regulatory network identified a fundamental role for XBP1 in regulating the response to hypoxia via the transcription factor hypoxia-inducible factor 1? (HIF1?). Importantly, activation of this pathway appears to carry prognostic implications, as expression of the XBP1-dependent signature is associated with shorter survival times in human TNBC.
    Type: Application
    Filed: February 23, 2017
    Publication date: August 24, 2017
    Inventors: Laurie H. GLIMCHER, Xi CHEN
  • Publication number: 20160237429
    Abstract: Described herein is a previously unknown function of XBP1 in controlling anti-tumor immunity. It is shown that inhibiting XBP1 in tumor-associated dendritic cells inhibits tumor growth and induces protective anti-tumor immune responses.
    Type: Application
    Filed: September 25, 2014
    Publication date: August 18, 2016
    Applicant: CORNELL UNIVERSITY
    Inventors: Juan R. CUBILLOS-RUIZ, Laurie H. GLIMCHER
  • Patent number: 8940479
    Abstract: The invention provides methods and compositions for modulating the expression, processing, post-translational modification, stability and/or activity of XBP-1 protein, or a protein in a signal transduction pathway involving XBP-I to treat dyslipidemias and steatosis disorders. The present invention also pertains to methods for identifying compounds that modulate the expression, processing, post-translational modification, and/or activity of XBP-I protein or a molecule in a signal transduction pathway involving XBP-1.
    Type: Grant
    Filed: January 14, 2009
    Date of Patent: January 27, 2015
    Assignee: Cornell University
    Inventors: Ann-Hwee Lee, Laurie H. Glimcher
  • Publication number: 20150018406
    Abstract: Described herein is a previously unknown function of XBP1 in triple-negative breast cancer (TNBC). It is shown that XBP1 is preferentially spliced and activated in TNBC, and that deletion of XBP1 significantly blocks triple negative breast tumor growth. Strikingly, XBP1 is required for the self-renewal of breast tumor initiating cells (TICs). Genome-wide mapping of the XBP1 transcriptional regulatory network identified a fundamental role for XBP1 in regulating the response to hypoxia via the transcription factor hypoxia-inducible factor 1a (HIF1a). Importantly, activation of this pathway appears to carry prognostic implications, as expression of the XBP1-dependent signature is associated with shorter survival times in human TNBC.
    Type: Application
    Filed: March 11, 2013
    Publication date: January 15, 2015
    Inventors: Laurie H. Glimcher, Xi Chen
  • Patent number: 8685388
    Abstract: The present invention relates to a method for the prevention, treatment and reduction of gastro-intestinal inflammation in a subject by administering a specific Bifidobacterium bacteria, in particular a fermented dairy product comprising said specific Bifidobacterium bacteria for the prevention, treatment and reduction of gastro-intestinal inflammation, in particular for the prevention and treatment of inflammatory bowel disease (IBD), ulcerative colitis (UC) and/or Crohn's Disease (CD) and for the prevention and treatment of Irritable Bowel Syndrome (IBS).
    Type: Grant
    Filed: November 2, 2009
    Date of Patent: April 1, 2014
    Assignees: Compagnie Gervais Danone, President and Fellows of Harvard College
    Inventors: Patrick Veiga, Isabelle Chambaud, Artem Khlebnikov, Laurie H. Glimcher, Wendy S. Garrett
  • Publication number: 20140030294
    Abstract: The invention provides, e.g., compositions and methods for increasing activation of immune cells.
    Type: Application
    Filed: February 7, 2012
    Publication date: January 30, 2014
    Applicant: CORNELL UNIVERSITY
    Inventor: Laurie H. Glimcher
  • Publication number: 20130202533
    Abstract: This invention is based, at least in part, on the discovery that Shn2 and Shn3 play an important role in skeletal remodeling and skeletal patterning. Accordingly, the present invention provides methods for identifying medulators of Shn2 activity and methods for modulating bone formation and mineralization and Shn2-associated disorders using agents that modulate Shn2 expression and/or activity, in addition to methods for modulating Shn2 and Shn3.
    Type: Application
    Filed: January 13, 2011
    Publication date: August 8, 2013
    Applicant: PRESIDENT AND FELLOWS OF HARVARD COLLEGE
    Inventors: Laurie H. Glimcher, Dallas C. Jones, Marc Wein
  • Patent number: 8389792
    Abstract: The instant invention is based, at least in part, on the discovery that T-bet maintains host commensal relationships in the gastrointestinal tract. Accordingly, this invention provides methods of treating and/or preventing ulcerative colitis, and/or colon cancer, and/or preventing colonization of a subject's gastrointestinal tract with commensal bacteria that promote ulcerative colitis as well as methods of identifying agents that treat and prevent the same.
    Type: Grant
    Filed: March 24, 2010
    Date of Patent: March 5, 2013
    Assignee: Cornell University
    Inventors: Laurie H. Glimcher, Wendy Sarah Garrett